1. Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes.
- Author
-
Shafaattalab S, Lin E, Christidi E, Huang H, Nartiss Y, Garcia A, Lee J, Protze S, Keller G, Brunham L, Tibbits GF, and Laksman Z
- Subjects
- Adenine analogs & derivatives, Atrial Fibrillation diagnosis, Atrial Fibrillation physiopathology, Cardiotoxicity diagnosis, Cardiotoxicity physiopathology, Cell Differentiation, Cells, Cultured, Heart physiopathology, Heart Atria cytology, Heart Atria drug effects, Heart Atria physiopathology, Heart Ventricles cytology, Heart Ventricles drug effects, Heart Ventricles physiopathology, Humans, Myocytes, Cardiac cytology, Organ Specificity, Piperidines, Pluripotent Stem Cells cytology, Protein Kinase Inhibitors pharmacology, Heart drug effects, Myocardium cytology, Myocytes, Cardiac drug effects, Pluripotent Stem Cells drug effects, Pyrazoles pharmacology, Pyrimidines pharmacology
- Abstract
Ibrutinib (IB) is an oral Bruton's tyrosine kinase (BTK) inhibitor that has demonstrated benefit in B cell cancers, but is associated with a dramatic increase in atrial fibrillation (AF). We employed cell-specific differentiation protocols and optical mapping to investigate the effects of IB and other tyrosine kinase inhibitors (TKIs) on the voltage and calcium transients of atrial and ventricular human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs). IB demonstrated direct cell-specific effects on atrial hPSC-CMs that would be predicted to predispose to AF. Second-generation BTK inhibitors did not have the same effect. Furthermore, IB exposure was associated with differential chamber-specific regulation of a number of regulatory pathways including the receptor tyrosine kinase pathway, which may be implicated in the pathogenesis of AF. Our study is the first to demonstrate cell-type-specific toxicity in hPSC-derived atrial and ventricular cardiomyocytes, which reliably reproduces the clinical cardiotoxicity observed., (Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF